
Cannabist
Patient-center healthcare company setting th standard of care for medical marijuana.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 Valuation: €0.0 4.1x EV/Revenue 31.3x EV/EBITDA | round | |
N/A | €0.0 | round | |
* | N/A | $19.5m | Post IPO Convertible |
Total Funding | 000k |




USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 134 % | 163 % | 8 % | - | (10 %) | (25 %) | - |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (2 %) | 18 % | 13 % | 14 % | 12 % | 11 % | 15 % |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (62 %) | (30 %) | (81 %) | (34 %) | - | (44 %) | (23 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
The Cannabist Company, which rebranded from its original name Columbia Care in 2023, stands as a significant entity in the American cannabis sector. It operates as a vertically integrated company, involved in the cultivation, manufacturing, and retail of cannabis products. The firm was co-founded by Michael Abbott and Nicholas Vita, who have served as Executive Co-Chairmen. Their professional backgrounds are rooted in finance and investment, with both having held significant roles at institutions like Goldman Sachs. This experience in highly regulated and complex markets provided a solid foundation for navigating the intricate legal and financial landscape of the U.S. cannabis industry.
The company's journey began with a focus on the medical cannabis market, establishing itself as an early provider in the United States. This patient-centric approach has since broadened to encompass the adult-use recreational market, reflecting the evolving legal framework across the country. The business model involves direct-to-consumer sales through its network of dispensaries, branded as Cannabist. These retail locations are designed to provide an educational and accessible experience for both medicinal patients and recreational consumers. Revenue is generated through the sale of a diverse portfolio of cannabis products.
The Cannabist Company's product offerings cover various consumption methods, including traditional flower, edibles, oils, and tablets. It has developed and markets several in-house brands to cater to different consumer segments. These brands include Seed & Strain, which focuses on cannabis flower, and Hedy, which is a line of edibles. By controlling the process from seed to sale, the company aims to ensure product quality and consistency across its operations. This vertical integration also allows it to capture margin at each stage of the value chain, from cultivation to final retail sale.
Keywords: cannabis, vertical integration, medical cannabis, adult-use cannabis, dispensary retail, cannabis cultivation, consumer packaged goods, cannabis manufacturing, brand portfolio, seed-to-sale
Tech stack
Investments by Cannabist
Edit



